Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy

Since 2005, the approved first-line treatment of metastatic renal cell carcinoma consists in tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor receptors (VEGFRs). Axitinib is an oral second-generation TKI and a potent VEGFR inhibitor with a half maximal inhibitory co...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellesoeur, Audrey, Carton, Edith, Alexandre, Jerome, Goldwasser, Francois, Huillard, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614734/
https://www.ncbi.nlm.nih.gov/pubmed/29033542
http://dx.doi.org/10.2147/DDDT.S109640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614734/
https://www.ncbi.nlm.nih.gov/pubmed/29033542
http://dx.doi.org/10.2147/DDDT.S109640

Ejemplares similares